These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 26296295)

  • 1. A phase I study of daily afatinib, an irreversible ErbB family blocker, in combination with weekly paclitaxel in patients with advanced solid tumours.
    Suder A; Ang JE; Kyle F; Harris D; Rudman S; Kristeleit R; Solca F; Uttenreuther-Fischer M; Pemberton K; Pelling K; Schnell D; de Bono J; Spicer J
    Eur J Cancer; 2015 Nov; 51(16):2275-84. PubMed ID: 26296295
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of pulsatile 3-day administration of afatinib (BIBW 2992) in combination with docetaxel in advanced solid tumors.
    Awada AH; Dumez H; Hendlisz A; Wolter P; Besse-Hammer T; Uttenreuther-Fischer M; Stopfer P; Fleischer F; Piccart M; Schöffski P
    Invest New Drugs; 2013 Jun; 31(3):734-41. PubMed ID: 23161334
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer.
    Schneeweiss A; Park-Simon TW; Albanell J; Lassen U; Cortés J; Dieras V; May M; Schindler C; Marmé F; Cejalvo JM; Martinez-Garcia M; Gonzalez I; Lopez-Martin J; Welt A; Levy C; Joly F; Michielin F; Jacob W; Adessi C; Moisan A; Meneses-Lorente G; Racek T; James I; Ceppi M; Hasmann M; Weisser M; Cervantes A
    Invest New Drugs; 2018 Oct; 36(5):848-859. PubMed ID: 29349598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase Ib, open-label, dose-escalation study of the safety and pharmacology of taselisib (GDC-0032) in combination with either docetaxel or paclitaxel in patients with HER2-negative, locally advanced, or metastatic breast cancer.
    Abramson VG; Oliveira M; Cervantes A; Wildiers H; Patel MR; Bauer TM; Bedard PL; Becerra C; Richey S; Wei MC; Reyner E; Bond J; Cui N; Wilson TR; Moore HM; Saura C; Krop IE
    Breast Cancer Res Treat; 2019 Nov; 178(1):121-133. PubMed ID: 31368034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase I study of paclitaxel and continuous daily CAI in patients with refractory solid tumors.
    Azad N; Perroy A; Gardner E; Imamura CK; Graves C; Sarosy GA; Minasian L; Kotz H; Raggio M; Figg WD; Kohn EC
    Cancer Biol Ther; 2009 Oct; 8(19):1800-5. PubMed ID: 19738417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Once daily cediranib and weekly paclitaxel to prevent malignant bowel obstruction in at-risk patients with platinum-resistant ovarian cancer (CEBOC): a single-arm, phase II safety trial.
    Murphy AD; Porter C; White A; Irving A; Adams R; Ray R; Casbard A; Mahmood RD; Karanth S; Zhou C; Pugh J; Wheeler C; Roberts V; Arnetoli G; Salih Z; Hasan J; Mitchell C; Morgan RD; Clamp AR; Jayson GC
    Int J Gynecol Cancer; 2024 Jul; 34(7):1034-1040. PubMed ID: 38724236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase 1 trial of the MEK inhibitor selumetinib in combination with pembrolizumab for advanced or metastatic solid tumors.
    Chénard-Poirier M; Hansen AR; Gutierrez ME; Rasco D; Xing Y; Chen LC; Zhou H; Webber AL; Freshwater T; Sharma MR
    Invest New Drugs; 2024 Jun; 42(3):241-251. PubMed ID: 38483782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I ficlatuzumab monotherapy or with erlotinib for refractory advanced solid tumours and multiple myeloma.
    Patnaik A; Weiss GJ; Papadopoulos KP; Hofmeister CC; Tibes R; Tolcher A; Isaacs R; Jac J; Han M; Payumo FC; Cotreau MM; Ramanathan RK
    Br J Cancer; 2014 Jul; 111(2):272-80. PubMed ID: 24901237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and pharmacokinetic study of dacomitinib (PF-00299804), an oral irreversible, small molecule inhibitor of human epidermal growth factor receptor-1, -2, and -4 tyrosine kinases, in Japanese patients with advanced solid tumors.
    Takahashi T; Boku N; Murakami H; Naito T; Tsuya A; Nakamura Y; Ono A; Machida N; Yamazaki K; Watanabe J; Ruiz-Garcia A; Imai K; Ohki E; Yamamoto N
    Invest New Drugs; 2012 Dec; 30(6):2352-63. PubMed ID: 22249430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer.
    Modjtahedi H; Cho BC; Michel MC; Solca F
    Naunyn Schmiedebergs Arch Pharmacol; 2014 Jun; 387(6):505-21. PubMed ID: 24643470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I dose-escalation study of pulsatile afatinib in patients with recurrent or progressive brain cancer.
    Juarez TM; Gill JM; Heng A; Carrillo JA; Wagle N; Nomura N; Nguyen M; Truong J; Dobrawa L; Sivakumar W; Barkhoudarian G; Kelly DF; Kesari S
    Neurooncol Adv; 2024; 6(1):vdae049. PubMed ID: 38680990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase I study of TAK-659 and paclitaxel in patients with taxane-refractory advanced solid tumors.
    Gouda MA; Shunyakova J; Naing A; Dumbrava E; Hong DS; Yuan Y; Yang P; Myers A; Liang Y; Peng J; Karp D; Tsimberidou AM; Rodon J; Yap TA; Piha-Paul SA; Meric-Bernstam F; Fu S
    ESMO Open; 2024 Jun; 9(6):103486. PubMed ID: 38914452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 1/2a Study of Rivoceranib, a Selective VEGFR-2 Angiogenesis Inhibitor, in Patients with Advanced Solid Tumors.
    Kang YK; Ryu MH; Hong YS; Choi CM; Kim TW; Ryoo BY; Kim JE; Weis JR; Kingsford R; Park CH; Jang S; McGinn A; Werner TL; Sharma S
    Cancer Res Treat; 2024 Jul; 56(3):743-750. PubMed ID: 38271925
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Phase 1 Study of Intravenous EGFR-ErbituxEDVsMIT in Children with Solid or CNS Tumours Expressing Epidermal Growth Factor Receptor.
    Evans L; Walker R; MacDiarmid J; Brahmbhatt H; Anazodo A; McCowage G; Gifford AJ; Kavallaris M; Trahair T; Ziegler DS
    Target Oncol; 2024 May; 19(3):333-342. PubMed ID: 38546944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of afatinib in the treatment of patients with HER2-positive breast cancer.
    Geuna E; Montemurro F; Aglietta M; Valabrega G
    Breast Cancer (Dove Med Press); 2012 Aug; 4():131-7. PubMed ID: 24367201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling Exposure-Driven Adverse Event Time Courses in Oncology Exemplified by Afatinib.
    Niebecker R; Maas H; Staab A; Freiwald M; Karlsson MO
    CPT Pharmacometrics Syst Pharmacol; 2019 Apr; 8(4):230-239. PubMed ID: 30681293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Afatinib in Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations Pretreated With Reversible EGFR Inhibitors.
    Heigener DF; Schumann C; Sebastian M; Sadjadian P; Stehle I; Märten A; Lüers A; Griesinger F; Scheffler M;
    Oncologist; 2015 Oct; 20(10):1167-74. PubMed ID: 26354527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase II study of afatinib, an irreversible ErbB family blocker, added to letrozole in patients with estrogen receptor-positive hormone-refractory metastatic breast cancer progressing on letrozole.
    Gunzer K; Joly F; Ferrero JM; Gligorov J; de Mont-Serrat H; Uttenreuther-Fischer M; Pelling K; Wind S; Bousquet G; Misset JL
    Springerplus; 2016; 5():45. PubMed ID: 26835225
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
    Marquez-Medina D; Popat S
    Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized Phase II Trial of Erlotinib Beyond Progression in Advanced Erlotinib-Responsive Non-Small Cell Lung Cancer.
    Halmos B; Pennell NA; Fu P; Saad S; Gadgeel S; Otterson GA; Mekhail T; Snell M; Kuebler JP; Sharma N; Dowlati A
    Oncologist; 2015 Nov; 20(11):1298-303. PubMed ID: 26306902
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.